ArticleJournal of clinical laboratory analysis2026
Asprosin as a Potential Link Between Vascular Inflammation and Disease Activity in Behçet's Disease.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Bidirectional C1q/TNF-Related Protein Signature Is Associated with Disease Activity in Behçet's Disease: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Inflammatory Prognostic Markers in COPD: Clinical Utility of CAR and MGPS.Journal of clinical medicine · 2026Article
- From inflammation to rupture: advances in the pathogenesis of pseudoaneurysm formation in Vascular Behçet's Disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBehçet's disease (BD) is a chronic multisystem vasculitis characterized by endothelial dysfunction and vascular inflammation. Asprosin is a recently identified adipokine implicated in endothelial injury and proinflammatory signaling. This study aimed to investigate serum asprosin concentrations in patients with BD and their relationship with disease activity and major clinical manifestations.
methodsThis cross-sectional case-control study enrolled 49 patients who fulfilled the International Criteria for Behçet's Disease and 48 healthy controls. Disease activity was stratified as mild, moderate, or severe based on organ involvement using Yosipovitch's Behçet's Disease Classification. Serum asprosin levels were quantified using an enzyme-linked immunosorbent assay. Associations among asprosin levels, disease activity, clinical manifestations, and inflammatory markers were analyzed.
resultsSerum asprosin concentrations were markedly elevated in individuals with Behçet's disease relative to healthy controls [12.18 (8.27-16.76) vs. 6.12 (4.76-8.61) ng/mL, p < 0.001] and increased incrementally as disease activity intensified (p < 0.001). Patients with vascular involvement and uveitis demonstrated markedly elevated asprosin levels compared to patients without these manifestations (p < 0.01). Correlation analysis revealed a strong positive association between serum asprosin levels and disease activity (r = 0.821, p < 0.001), and a moderate correlation with C-reactive protein (CRP) levels (r = 0.431, p = 0.002). In multivariate analysis, both disease activity and CRP levels were independently associated with serum asprosin concentrations.
conclusionSerum asprosin levels are elevated in BD and closely associated with disease activity, systemic inflammation, and major organ involvement, particularly vascular manifestations and uveitis. Asprosin may represent a potential biomarker of the inflammatory and vascular burden in BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.